What this means for us is that if we can meet or exceed their results we will also be approved. They had 98% specificity and 9.5% sensitivity.
The Aura:
Jointly developed by the BC Cancer Agency and the University of British Columbia Faculty of Medicine, this patent protected technology has already been used in a human clinical study spanning six years on approximately 1,000 lesions. Preliminary results published in 2008 showed the technology had found every case of melanoma in 274 lesions flagged for biopsy. This diagnostic tool will greatly aid healthcare professionals, lowering healthcare costs through reduced wait times and early detection.
Verisante Aura™ will help to automate the current process of diagnosis, allowing rapid scanning of the 20-40 skin lesions on at-risk individuals. Patients will no longer need to suffer through long wait times to see a dermatologist, as scans may be accomplished quickly by trained technicians or assistants. Verisante Aura™ will decrease patient wait times, thereby increasing the standard of care; while also decreasing healthcare costs by detecting skin cancer in its early, most easily treatable stages.The Verisante Core™ series utilizes the platform technology behind the Verisante Aura™ for the early detection of other cancers including lung, colon and cervical, using an endoscopic attachment.
The first use for Verisante Core™ will be to aid in the early detection of lung cancer. The device has already been used by the BC Cancer Agency on over 50 patients with excellent results. The study was done by the BC Cancer Agency in collaboration with the Lung Centre at Vancouver General Hospital.
The optical biopsy system, known as the Verisante Core™ series, detects spectral bio-markers for cancer. Today, once a doctor spots a lung lesion, it must be surgically biopsied for a full pathology report to determine if it is malignant. However, the Verisante Core™ device determines with exceptional accuracy if a lesion is malignant or benign. Through this quick and non-invasive verification process, the Verisante Core™ device prevents unnecessary biopsies and the resulting stress and health-care risks and costs that accompany the biopsy procedure.
In addition to our existing collaborations with the BC Cancer Agency, Verisante will collaborate with Dr. Stephen Lam and the VGH Lung Centre for the development and commercialization of Verisante Core™ for the early detection of lung cancer.
Market Data 
Markets 
AI
